RE:RE:certianly worth a watchThe sp gaining traction or legs, is a million $ question.
everything regarding any share price is relative. Meaning from what point ....to what point.
If you look, there has been a 75% increase since the near all time low, back in May.
from around $1.30 to now $2.12-$2.25. Etc
That of course is meaningless to those who bought above $10ps back in 2017/18.
The SP, has been on a longer trend recovery since May.
within that short term spikes & corrections.
The stronger SP action IMHO will not be market driven. It will be event driven.
The recent Pancrestic cancer results alongside Roche, alone puts Onc well above the $5ps and abov3 the $6ps that RBC has as a target.
They preface that number with an $18ps upside, with the following
1. more solid resukts around panc & MBc ( expected partially Dec 7th).
2. A $$$ partnership announcement...Thst is expected to move off of the upcoming data.
3. A complete buy- out....Onc is in combination trials with Roche, Pfizer, Incyte, & Merck. Any of which could buyout Onc at any moment.
of all th3 above, the only thing we know for sure. Onc has 2 presentations at the San Antonio breast cancer symposium. Dec 7th.
it will be good news clinically. The business development?
depends how big pharm sees thst news.